Neurotoxin

Department of Defense Awards Ology Bioservices Contract to Advance Anti-Botulinum Neurotoxin Monoclonal Antibodies

Thursday, June 25, 2020 - 8:45pm

In this program, Ology Bioservices will execute a randomized, double-blinded Phase 1 dose-escalation clinical trial of a cocktail of mAb against botulinum neurotoxin serotypes A and B.

Key Points: 
  • In this program, Ology Bioservices will execute a randomized, double-blinded Phase 1 dose-escalation clinical trial of a cocktail of mAb against botulinum neurotoxin serotypes A and B.
  • Ology Bioservices successfully transferred the technology and manufactured this candidate therapeutic for the DOD under a previous contract awarded in 2017.
  • This contract is an important milestone for both Ology Bioservices and the DOD, said Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bioservices.
  • Monoclonal antibodies represent an important, innovative option in medical countermeasure development, allowing the DOD to more effectively layer CBRN defense.

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Effect of Climate Change on the Brain, Link to Alzheimer's and Parkinson's, to be Key Focus of Discussion at XXIV World Congress of Neurology

Tuesday, October 29, 2019 - 1:33pm

The environmental impact of climate change could, in fact, be a brain health emergency, the effects of which are a major focus of the XXIV World Congress of Neurology (WCN 2019) in Dubai, UAE, October 27-31, 2019.

Key Points: 
  • The environmental impact of climate change could, in fact, be a brain health emergency, the effects of which are a major focus of the XXIV World Congress of Neurology (WCN 2019) in Dubai, UAE, October 27-31, 2019.
  • People worldwide are exposed to "invisible" pollutants and neurotoxins in the atmospheric air, food and water, that are capable of affecting the nervous system.
  • A report released by the World Health Organization listed air pollution and climate change as the number one threat in 2019.
  • With support from member organizations, the WFN unifies the world to give patients better access to brain health.

Effect of Climate Change on the Brain, Link to Alzheimer's and Parkinson's, to be Key Focus of Discussion at XXIV World Congress of Neurology

Tuesday, October 29, 2019 - 1:21pm

The environmental impact of climate change could, in fact, be a brain health emergency, the effects of which are a major focus of the XXIV World Congress of Neurology (WCN 2019) in Dubai, UAE, October 27-31, 2019.

Key Points: 
  • The environmental impact of climate change could, in fact, be a brain health emergency, the effects of which are a major focus of the XXIV World Congress of Neurology (WCN 2019) in Dubai, UAE, October 27-31, 2019.
  • People worldwide are exposed to "invisible" pollutants and neurotoxins in the atmospheric air, food and water, that are capable of affecting the nervous system.
  • A report released by the World Health Organization listed air pollution and climate change as the number one threat in 2019.
  • With support from member organizations, the WFN unifies the world to give patients better access to brain health.

Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK

Wednesday, June 5, 2019 - 9:00am

Practice is governed by professional organisations and should comply with national guidelines such as the Royal College of Physicians for adult spasticity.

Key Points: 
  • Practice is governed by professional organisations and should comply with national guidelines such as the Royal College of Physicians for adult spasticity.
  • [2]
    Dr. Marie-Helene Marion, Chair of the British Neurotoxin Network says "Botulinum toxin type A therapies have been a standard of care for a range of therapeutic areas including spasticity for many years.
  • We wholeheartedly support this expansion to the range of specially trained healthcare professionals who are able to administer these vital medicines".
  • Abnormal muscle contraction produced by spasticity cause limbs to lose their flexibility leading to pain and a reduction in mobility.

Ipsen's Dysport® (Clostridium Botulinum Type a Toxin-haemagglutinin Complex) Becomes First and Only Botulinum Toxin Type A to be Granted a Licence Update for Administration by Healthcare Professionals, Such as Physiotherapists, in the UK

Wednesday, June 5, 2019 - 9:00am

Practice is governed by professional organisations and should comply with national guidelines such as the Royal College of Physicians for adult spasticity.

Key Points: 
  • Practice is governed by professional organisations and should comply with national guidelines such as the Royal College of Physicians for adult spasticity.
  • [2]
    Dr. Marie-Helene Marion, Chair of the British Neurotoxin Network says "Botulinum toxin type A therapies have been a standard of care for a range of therapeutic areas including spasticity for many years.
  • We wholeheartedly support this expansion to the range of specially trained healthcare professionals who are able to administer these vital medicines".
  • Abnormal muscle contraction produced by spasticity cause limbs to lose their flexibility leading to pain and a reduction in mobility.

Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief

Friday, January 18, 2019 - 6:30am

The survey1, undertaken in association with Carenity, a social media platform for people living with chronic diseases, also exposes the practical issues related to spasticity and its treatment.

Key Points: 
  • The survey1, undertaken in association with Carenity, a social media platform for people living with chronic diseases, also exposes the practical issues related to spasticity and its treatment.
  • The patients perspective on botulinum neurotoxin A treatment: results of a multinational survey for patients with spasticity; Bahroo et al.
  • Fewer injections of botulinum toxin type A for treatment of spasticity are perceived as beneficial by both patients and caregivers; Wein et al.
  • Time to retreatment with botulinum toxin A in upper limb spasticity management: upper limb international spasticity (ULIS)-III study interim analysis; Turner-Stokes et al.